BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
토요일, 9월 26

ACADIA Pharmaceuticals Inc

ACADNASDAQ
Trade with Public
Trade with Public
$20.68
-1.50-6.76%
가까이에: Sep 25, 5:00 PM EST
$20.69
0.01210.06%
시간외: 7:54 PM EST
PRO
변동 이유?:ACADIA Pharmaceuticals shares are trading lower after multiple analyst firm...
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

ACADIA Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for ACADIA Pharmaceuticals (ACAD).

Price Target Range — 9 Quarters

Analyst Consensus — 21 Analysts

2S.Buy
15Buy
3Hold
1Sell
Consensus RatingBuy# Analysts21Avg. Consensus PT$31Upside to Avg. PT+48.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 25, 2026Deutsche BankDavid HoangPT CutBuy$38→$31
Sep 25, 2026HC Wainwright & Co.Ananda GhoshPT CutBuy$37→$33
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $31

Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $38 to $31.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33

HC Wainwright & Co. analyst Ananda Ghosh maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $37 to $33.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33

Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and lowers the price target from $36 to $33.
Benzinga Newsdesk

PRO
BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $34

BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $36 to $34.
Benzinga Newsdesk

PRO
Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $35

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $41 to $35.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $40 to $33.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved